Pay in 4 interest-free payments of $6.38 Learn more
Ships within 48 hours · Estimated delivery Aug 18 - Aug 23
When your skin is exposed to the sun, it produces more melanin to shield deeper layers from damage
Supports Anti-Aging Goals Growth hormone naturally declines with age
Around the two-week mark, most patients begin to notice physical changes in the abdominal area
Approval: 1978 Indications and Usage for DDAVP Nasal Spray DDAVP Nasal Spray is a vasopressin analog indicated as antidiuretic replacement therapy in the management of central diabetes insipidus for adults and pediatric patients 4 years of age and older (1) Limitations of Use: DDAVP Nasal Spray is not indicated for: Treatment of nephrogenic diabetes insipidus (1) Treatment of primary nocturnal enuresis (1, 5.1) Use in patients with conditions that compromise intranasal route of administration (1, 5.2) Use in patients with an impaired level of consciousness (1) Use in patients requiring doses less than 10 mcg or doses that are not multiples of 10 mcg (1,3) DDAVP Nasal Spray Dosage and Administration For intranasal use only (2.1) Instruct patients to prime pump prior to use (2.1) Adults: 10 mcg to 40 mcg daily (either as a single dose or divided into two or three daily doses) (2.2) Pediatrics: 10 mcg once daily into one nostril up to 30 mcg once daily (or 30 mcg divided as 20 mcg during the morning and 10 mcg at night) (2.2) See the Full Prescribing Information for recommendations for switching between desmopressin acetate formulations (2.3) Dosage Forms and Strengths Nasal Spray: 10 mcg per 0.1 mL spray, available in a 5 mL bottle with spray pump delivering 50 sprays (3) Contraindications Warnings and Precautions Adverse Reactions/Side Effects Adverse reactions that have been identified in patients administered DDAVP Nasal Spray are headache, nasal congestion, rhinitis, nosebleed, sore throat, cough, upper respiratory infections, nausea, flushing, and mild abdominal cramps (6) To report SUSPECTED ADVERSE REACTIONS, contact Ferring Pharmaceuticals Inc
Restrictions, product changes, and supply issues will make margins swing and disrupt patient care
Additionally, a meta-analysis of 26 trials concluded that GLP-1RAs were particularly effective in reducing macrovascular and microvascular complications, positioning them as a strong therapeutic choice for patients at risk of cardiovascular and cerebrovascular disease
